Mpox Therapeutics and Vaccines Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Mpox Therapeutics and Vaccines remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 53 matched trial records and 14 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07634081 | Intervention not normalized | Not Applicable; Recruiting | Universitaire Ziekenhuizen KU Leuven | Democratic Republic of the Congo | Paired difference in mpox positivity between SDS-EDTA strip samples and routine swab samples. (Laboratory analysis of collected samples up to 6 months after collection) | 2026-07-31 |
| NCT07620600 | Intervention not normalized | Not Applicable; Not yet recruiting | Foundation for Innovative New Diagnostics | Geography not listed | Point estimates of sensitivity, specificity, positive and negative predictive value (PPV and NPV respectively) with 95% confidence intervals. (July-August 2026) | 2026-08-15 |
| NCT07592429 | Intervention not normalized | Not Applicable; Not yet recruiting | ANRS Emerging infectious diseases | Geography not listed | The main outcomes are: the presence of neutralizing antibodies in the serum and the presence of detectable mpox virus-specific memory B cells. (Baseline (Day 1)) | 2027-07-01 |
| NCT07534267 | Intervention not normalized | Not Applicable; Not yet recruiting | London School of Hygiene & Tropical Medicine | Guinea | Viral clearance in oropharyngeal swabs (From day 1 to day 56); Secondary attack rate of infection (From day 1 to day 14) | 2027-02-28 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Safety of MVA-BN vaccine in health-care personnel in DR Congo: a prospective cohort study (Phase 3): the indexed record reports AE = 49.0 %.
- A Phase 2 Randomized, Open-Label, Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox (Phase 2): the indexed record reports Vaccinia Virus Specific Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT)(Geometric Mean) = 295.7 titer (95% Confidence Interval, 240.8 - 363.2); Vaccinia Virus Specific Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT)(Geometric Mean): Geometric mean titer ratio (GMTR) = 1.60(95% CI, 1.32 - 1.95), P-Value = <0.001; Geometric mean titer ratio (GMTR) = 1.59(95% CI, 1.26 - 2.00), P-Value = <0.001; Vaccinia Virus Specific Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT)(Geometric Mean) = 293.2 titer (95% Confidence Interval, 249.8 - 344.2).
- Tecovirimat for the Treatment of Mpox (Phase 3): the indexed record reports Viral DNA clearance: HR = 0.98(95.0% CI, 0.74 - 1.31); Viral DNA clearance: HR = 0.98(95.0% CI, 0.74 - 1.31).
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including The selected trials include interventions that are not yet normalized to an asset record. Company & Deal Intelligence records identify sponsor context for Universitaire Ziekenhuizen KU Leuven, Foundation for Innovative New Diagnostics, ANRS Emerging infectious diseases, London School of Hygiene & Tropical Medicine. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Clinically meaningful endpoints paired with virologic or microbiologic measures.
- Evidence in immunocompromised, pediatric, pregnant and older populations.
- Resistance surveillance and combination strategies for prolonged infection.
- Coadministration, real-world effectiveness and implementation studies.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Mpox Therapeutics and Vaccines has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
